BioLineRx rallies on BL-8040 news


BioLineRx (BLRX) trades 22% higher before the bell.

Investors appear pleased with early results from a Phase 2 study of BL-8040 in AML.

Summary: BL-8040 (alone and in combination with Ara-C) is safe at the tested doses, triggers substantial mobilization of cancer cells from the bone marrow to the peripheral blood (the idea being to make them more susceptible to chemo), and, at higher doses, appears to have contributed to cancer cell death.

CEO Kinneret Savitsky is "very excited." (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs